METHYLPREDNISOLONE
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Glucocorticoid receptor agonist; inhibits phospholipase A2, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell activity.
| Metabolism | Hepatic via CYP3A4; primarily metabolized to inactive metabolites. |
| Excretion | Renal (primarily as inactive metabolites, <10% unchanged); minor biliary/fecal elimination |
| Half-life | Plasma: 2.5-3.5 hours; biological half-life (tissue): 18-36 hours due to glucocorticoid receptor-mediated effects; clinical context: anti-inflammatory effects persist beyond plasma clearance |
| Protein binding | ~77% bound to albumin and corticosteroid-binding globulin (CBG); binding is concentration-dependent |
| Volume of Distribution | 0.8-1.3 L/kg; indicates extensive tissue distribution, including intracellular sites of action |
| Bioavailability | Oral: 70-90% (immediate-release); IM: ~100%; intra-articular: local, minimal systemic absorption |
| Onset of Action | IV: rapid (minutes); IM: 1-2 hours; oral: 1-2 hours; intra-articular: 6-12 hours; topical: variable, within days |
| Duration of Action | Single dose: 12-36 hours (biological effects); duration depends on dose, route, and condition; short-term use for acute inflammation; prolonged therapy for chronic conditions |
4-48 mg/day orally in divided doses; 10-40 mg IV/IM bolus, then 10-40 mg IV q4-6h; high-dose IV pulse: 1 g/day for 3 days.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR >10 mL/min; for severe impairment (GFR <10 mL/min), use with caution and monitor for fluid retention. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: initiate at lowest dose, titrate carefully due to increased risk of toxicity. |
| Pediatric use | 0.5-2 mg/kg/day orally in divided doses; IV: 0.5-1 mg/kg/dose q6-24h; pulse therapy: 30 mg/kg IV over 30 min daily for 3 days. |
| Geriatric use | Initiate at lowest effective dose; monitor for hyperglycemia, osteoporosis, immunosuppression; adjust for comorbidities and drug interactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| Breastfeeding | Methylprednisolone is excreted into breast milk in low amounts (M/P ratio approximately 0.5-0.8). Peak milk concentration occurs 1-2 hours after maternal dose. With maternal doses up to 80 mg/day, infant dose is estimated <10% of maternal weight-adjusted dose, unlikely to cause adverse effects. Advise monitoring infant for adrenal suppression if prolonged high-dose therapy. |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio 3.35, 95% CI 1.97-5.69) with exposure. Second/third trimesters: Associated with fetal adrenal suppression, intrauterine growth restriction, and preterm birth. Chronic use may cause neonatal adrenal insufficiency. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | immunosuppression |
| Serious Effects |
["Systemic fungal infections","Hypersensitivity to methylprednisolone or any component","Intrathecal administration (contraindicated)","Live or live-attenuated vaccines (relative)","Idiopathic thrombocytopenic purpura (IM administration)"]
| Precautions | ["Adrenal suppression and insufficiency with prolonged use or rapid withdrawal","Increased risk of infections","Masking of infection signs","Gastrointestinal perforation (especially with NSAIDs)","Osteoporosis with long-term use","Cataracts and glaucoma","Cushing's syndrome with high doses","Kaposi sarcoma reported"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, blood pressure, and signs of infection. Fetal ultrasound for growth restriction if used chronically. Newborn should be monitored for adrenal insufficiency (e.g., hypoglycemia, hypotension) if exposed in late pregnancy. |
| Fertility Effects | No known adverse effect on fertility. Chronic use may suppress hypothalamic-pituitary-adrenal axis but does not directly impair gametogenesis or reproductive function. |